ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,644Medicare Part D Prescriptions Filled, Including Refills

Rank: 15 out of 300

$1.33M Total Retail Price of All Prescriptions

Rank: 5 out of 300

788 Patients Receiving at Least One Drug in Part D
64%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

8% of this provider’s 788 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

0% of this provider’s 6,347 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 4%.

Brand Name Drugs

55% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$138 was the average price of a prescription from this provider, compared to $81 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
SYNTHROID 1,147 756 1 49
LEVOTHYROXINE SODIUM 484 311 2 9
PEN NEEDLE 303 198 3 194
GLIMEPIRIDE 302 238 4 51
ZOLPIDEM TARTRATE 263 160 5 21
JANUMET 242 179 6 235
VICTOZA 3-PAK 215 131 7 273
TRADJENTA 195 157 10 8 281
METFORMIN HCL ER 194 89 9 131
JANUVIA 161 121 10 100
CLONAZEPAM 156 98 11 162
ATORVASTATIN CALCIUM 150 108 12 14
INSULIN SYRINGE 146 95 13 156
LANTUS 145 84 14 125
CRESTOR 137 93 15 26
LANTUS SOLOSTAR 135 102 16 212
FUROSEMIDE 126 86 17 3
LEVOXYL 121 76 18 260
HUMULIN R 109 71 19 348
ONGLYZA 108 91 20 231
PRAVASTATIN SODIUM 105 86 21 15
BUPROPION XL 98 68 22 171
FENOFIBRATE 98 79 22 98
BYETTA 96 69 24 359
LOVAZA 96 52 24 129
METFORMIN HCL 95 69 26 19
KOMBIGLYZE XR 93 46 27 362
SIMVASTATIN 92 56 28 5
BYDUREON 89 59 29 365
NOVOLOG 85 31 30 229
LEVEMIR FLEXPEN 83 60 31 306
LIOTHYRONINE SODIUM 82 50 32 369
PRANDIN 69 63 33 386
ANDROGEL 68 36 S3 34 313
ATENOLOL 68 45 34 31
AMLODIPINE BESYLATE-BENAZEPRIL 68 67 34 52
METOPROLOL SUCCINATE 65 57 37 6
CYMBALTA 64 34 38 37
EXFORGE 63 44 39 175
SYMLINPEN 120 62 41 10 40 400
LOSARTAN-HYDROCHLOROTHIAZIDE 61 46 41 97
HUMALOG 61 28 41 328
NOVOLOG FLEXPEN 60 37 43 300
AMLODIPINE BESYLATE 58 50 44 2
METHIMAZOLE 58 26 44 413
NEXIUM 56 24 46 17
LUNESTA 53 33 47 239
DIOVAN 52 39 48 46
SERTRALINE HCL 51 35 49 41
TESTOSTERONE CYPIONATE 50 25 S3 50 445
LIPITOR 50 34 50 115
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 20, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.